| __timestamp | Amphastar Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 5496000 |
| Thursday, January 1, 2015 | 46974000 | 9786000 |
| Friday, January 1, 2016 | 47298000 | 6792000 |
| Sunday, January 1, 2017 | 50918000 | 7313000 |
| Monday, January 1, 2018 | 58044000 | 8382000 |
| Tuesday, January 1, 2019 | 63109000 | 10803000 |
| Wednesday, January 1, 2020 | 65157000 | 12944000 |
| Friday, January 1, 2021 | 68920000 | 21967000 |
| Saturday, January 1, 2022 | 66592000 | 32810000 |
| Sunday, January 1, 2023 | 80393000 | 46542000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Amphastar Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Amphastar's SG&A expenses have grown steadily, peaking in 2023 with an increase of nearly 100% from 2014. This consistent rise reflects Amphastar's commitment to expanding its market presence and operational capabilities.
Xenon, on the other hand, has demonstrated a more dramatic increase, with SG&A expenses surging by over 700% during the same period. This sharp rise, particularly noticeable from 2020 onwards, suggests a strategic pivot towards aggressive growth and innovation.
These contrasting spending patterns highlight the diverse strategies employed by pharmaceutical companies to navigate the ever-evolving healthcare landscape.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Analyzing R&D Budgets: Xenon Pharmaceuticals Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.